<?xml version="1.0" encoding="UTF-8"?>
<p id="Par3">The current study was approved by the Mayo Clinic institutional review board and all patients provided informed written consent for clinical trial participation, study sample collection as well as permission for its use in research. Patient eligibility criteria, study design, treatment plan, study test schedule, and other protocol details have previously been reported
 <sup>
  <xref ref-type="bibr" rid="CR1">1</xref>
 </sup>, and will not be reiterated here. The study population for the current study constitutes part of a larger phase 1/2 clinical trial (CCL09101; NCT00935987) using momelotinib for the treatment of MF; the results of which were recently communicated
 <sup>
  <xref ref-type="bibr" rid="CR5">5</xref>
 </sup>. Toxicity was graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Baseline transfusion status, anemia, and spleen responses were all defined according to the 2006 international working group for MPN research and treatment (IWG-MRT criteria)
 <sup>
  <xref ref-type="bibr" rid="CR6">6</xref>
 </sup>. Cytogenetic analysis and reporting was done according to the International System for Human Cytogenetic Nomenclature and assignment as "unfavorable karyotype‚Äù was according to the previously established criteria
 <sup>
  <xref ref-type="bibr" rid="CR7">7</xref>
 </sup>. Targeted next-generation sequencing was used to screen for prognostically relevant mutations
 <sup>
  <xref ref-type="bibr" rid="CR8">8</xref>,
  <xref ref-type="bibr" rid="CR9">9</xref>
 </sup>. Information on survival and leukemic transformation was updated in August 2017.
</p>
